Financing
Mesentech's last financing was $11M in 2022-Q2 with a post-money valuation of $26M. The next milestone is the first human biomarker readouts in 2023-Q4.
Pipeline
Our IP consists of New Chemical Entities (NCEs) and have composition of matter patents that also cover direct synthesis methods. Below are our current programs
For more information please Contact us
